BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

Ophthalmic deals Date Companies Value [upfront; milestones/royalties] Description Sep 08 Acucela/Otsuka (Tokyo:4768) [$5M; up to $258M] Partner to develop a pair of compounds for ophthalmic indications: Acucela's ACU-4429 for dry age-related macular degeneration (AMD) and...
BC Week In Review | Jun 16, 2008
Company News

Opko, Redox Pharmaceutical Corp. deal

Opko acquired exclusive, worldwide rights from Redox to develop and commercialize Doxovir ( CTC-96 ) for ophthalmic indications. The compound has completed Phase I trials to treat viral conjunctivitis and ocular herpes infection. Opko plans to begin...
BC Week In Review | Jun 14, 1999
Company News

Redox Pharmaceutical Corp., Trima Pharmaceutical Products Maarbarot Ltd. deal

The companies will evaluate the development of a product combining Redox’s Doxovir CTC-96 metallo-organic compound with Trima’s wound repair drug delivery vehicle to treat wounds. The companies also will collaborate on a formulation of Doxovir...
BC Week In Review | Jun 1, 1999
Company News

Redox Pharmaceutical Corp. other research news

Redox received an undisclosed Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases to develop its Doxovir to prevent genital herpes. Redox Pharmaceutical Corp., Southampton, N.Y.   Product: Doxovir CTC-96  ...
Items per page:
1 - 4 of 4